Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Positive clinical outcomes following ivacaftor treatment in a cystic fibrosis patient with the genotype 3272-26A > G/Q493X.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society - 1 Jan 2020

Pallin M, Daley C P

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Chloride Channel Agonists
Share to Cystic Fibrosis
Share to Cystic Fibrosis Transmembrane Conductance Regulator

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Quality of Life

Share to Quinolones

Share to Respiratory Function Tests

Share to Respiratory Tract Infections

Source

Identifiers

PMID: 31771899
DOI: 10.1016/j.jcf.2019.11.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Positive clinical outcomes following ivacaftor treatment in a cystic fibrosis patient with the genotype 3272-26A > G/Q493X.PMID 31771899Read ↗

Ivacaftor in a G551D homozygote with cystic fibrosis.Semantic proximity Read ↗

Tezacaftor-ivacaftor is safe and efficacious in patients with cystic fibrosis with Phe508del mutations.Semantic proximity Read ↗

Elexacaftor/Tezacaftor/Ivacaftor Effectiveness in N1303K Variant in Adult People With Cystic Fibrosis.Semantic proximity Read ↗

Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor in a man with A559T and 3120+1G>CFTR variants.Semantic proximity Read ↗

Elexacaftor-tezacaftor-ivacaftor: The new paradigm to treat people with cystic fibrosis with at least one p.Phe508del mutation.Semantic proximity Read ↗

The U.S. Food and Drug Administration's Experience with Ivacaftor in Cystic Fibrosis. Establishing Efficacy Using In Vitro Data in Lieu of a Clinical Trial.Semantic proximity Read ↗

Ivacaftor for cystic fibrosis.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR GenotypeSemantic proximity Read ↗

Cystic fibrosis papers of the year 2017.Semantic proximity Read ↗

Elexacaftor/tezacaftor/ivacaftor (Trikafta) for cystic fibrosis.Semantic proximity Read ↗

Real Life With Tezacaftor and Ivacaftor in Adult Patients With Cystic Fibrosis: Spanish Multicenter Study.Semantic proximity Read ↗

Cystic fibrosis: new challenges and perspectives beyond elexacaftor/tezacaftor/ivacaftor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.